Symptomatic Intracranial Hemorrhage After Stroke Thrombolysis: Comparison of Prediction Scores

Background and Purpose— Several prognostic scores have been developed to predict the risk of symptomatic intracranial hemorrhage (sICH) after ischemic stroke thrombolysis. We compared the performance of these scores in a multicenter cohort. Methods— We merged prospectively collected data of patients with consecutive ischemic stroke who received intravenous thrombolysis in 7 stroke centers. We identified and evaluated 6 scores that can provide an estimate of the risk of sICH in hyperacute settings: MSS (Multicenter Stroke Survey); HAT (Hemorrhage After Thrombolysis); SEDAN (blood sugar, early infarct signs, [hyper]dense cerebral artery sign, age, NIH Stroke Scale); GRASPS (glucose at presentation, race [Asian], age, sex [male], systolic blood pressure at presentation, and severity of stroke at presentation [NIH Stroke Scale]); SITS (Safe Implementation of Thrombolysis in Stroke); and SPAN (stroke prognostication using age and NIH Stroke Scale)-100 positive index. We included only patients with available variables for all scores. We calculated the area under the receiver operating characteristic curve (AUC-ROC) and also performed logistic regression and the Hosmer–Lemeshow test. Results— The final cohort comprised 3012 eligible patients, of whom 221 (7.3%) had sICH per National Institute of Neurological Disorders and Stroke, 141 (4.7%) per European Cooperative Acute Stroke Study II, and 86 (2.9%) per Safe Implementation of Thrombolysis in Stroke criteria. The performance of the scores assessed with AUC-ROC for predicting European Cooperative Acute Stroke Study II sICH was: MSS, 0.63 (95% confidence interval, 0.58–0.68); HAT, 0.65 (0.60–0.70); SEDAN, 0.70 (0.66–0.73); GRASPS, 0.67 (0.62–0.72); SITS, 0.64 (0.59–0.69); and SPAN-100 positive index, 0.56 (0.50–0.61). SEDAN had significantly higher AUC-ROC values compared with all other scores, except for GRASPS where the difference was nonsignificant. SPAN-100 performed significantly worse compared with other scores. The discriminative ranking of the scores was the same for the National Institute of Neurological Disorders and Stroke, and Safe Implementation of Thrombolysis in Stroke definitions, with SEDAN performing best, GRASPS second, and SPAN-100 worst. Conclusions— SPAN-100 had the worst predictive power, and SEDAN constantly the highest predictive power. However, none of the scores had better than moderate performance.

[1]  Mei-ChiunTseng,et al.  Comparison of Risk-scoring Systems in Predicting Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis , 2013 .

[2]  D. Jatužis,et al.  External Validation of the SEDAN Score for Prediction of Intracerebral Hemorrhage in Stroke Thrombolysis , 2013, Stroke.

[3]  D. Tanné,et al.  Validation Assessment of Risk Scores to Predict Postthrombolysis Intracerebral Haemorrhage , 2011, International journal of stroke : official journal of the International Stroke Society.

[4]  M. Kaste,et al.  Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis , 2011, Neurology.

[5]  M. Kaste,et al.  Predicting outcome of IV thrombolysis–treated ischemic stroke patients , 2012, Neurology.

[6]  Eric E. Smith,et al.  Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator , 2012, Stroke.

[7]  Catherine Oppenheim,et al.  Magnetic Resonance Imaging-DRAGON Score: 3-Month Outcome Prediction After Intravenous Thrombolysis for Anterior Circulation Stroke , 2013, Stroke.

[8]  R. Yufe.  Stroke prognostication using age and NIH Stroke Scale: SPAN-100 , 2013, Neurology.

[9]  Gustavo Saposnik,et al.  IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke , 2011, Circulation.

[10]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[11]  M. Kaste,et al.  Symptomatic intracranial hemorrhage after stroke thrombolysis: The SEDAN Score , 2012, Annals of neurology.

[12]  G Schlaug,et al.  The HAT Score , 2008, Neurology.

[13]  D. Tanné,et al.  A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[15]  J. Saver.  Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm , 2007, Stroke.

[16]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[17]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.